Literature DB >> 17698792

Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).

V Planté-Bordeneuve1, A Ferreira, T Lalu, C Zaros, C Lacroix, D Adams, G Said.   

Abstract

Transthyretin familial amyloid polyneuropathies (TTR-FAPs) are autosomal dominant neuropathies of fatal outcome within 10 years after inaugural symptoms. Late diagnosis in patients who present as nonfamilial cases delays adequate management and genetic counseling. Clinical data of the 90 patients who presented as nonfamilial cases of the 300 patients of our cohort of patients with TTR-FAP were reviewed. They were 21 women and 69 men with a mean age at onset of 61 (extremes: 38 to 78 years) and 17 different mutations of the TTR gene including Val30Met (38 cases), Ser77Tyr (16 cases), Ile107Val (15 cases), and Ser77Phe (5 cases). Initial manifestations included mainly limb paresthesias (49 patients) or pain (17 patients). Walking difficulty and weakness (five patients) and cardiac or gastrointestinal manifestations (five patients), were less common at onset. Mean interval to diagnosis was 4 years (range 1 to 10 years); 18 cases were mistaken for chronic inflammatory demyelinating polyneuropathy, which was the most common diagnostic error. At referral a length-dependent sensory loss affected the lower limbs in 2, all four limbs in 20, and four limbs and anterior trunk in 77 patients. All sensations were affected in 60 patients (67%), while small fiber dysfunction predominated in the others. Severe dysautonomia affected 80 patients (90%), with postural hypotension in 52, gastrointestinal dysfunction in 50, impotence in 58 of 69 men, and sphincter disturbance in 31. Twelve patients required a cardiac pacemaker. Nerve biopsy was diagnostic in 54 of 65 patients and salivary gland biopsy in 20 of 30. Decreased nerve conduction velocity, increased CSF protein, negative biopsy findings, and false immunolabeling of amyloid deposits were the main causes of diagnostic errors. We conclude that DNA testing, which is the most reliable test for TTR-FAP, should be performed in patients with a progressive length-dependent small fiber polyneuropathy of unknown origin, especially when associated with autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698792     DOI: 10.1212/01.wnl.0000267338.45673.f4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.

Authors:  Marco Luigetti; Amelia Conte; Alessandra Del Grande; Giulia Bisogni; Francesca Madia; Mauro Lo Monaco; Luca Laurenti; Laura Obici; Giampaolo Merlini; Mario Sabatelli
Journal:  Neurol Sci       Date:  2012-05-17       Impact factor: 3.307

Review 2.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

3.  Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci.

Authors:  Haruki Koike; Yuichi Kawagashira; Masahiro Iijima; Masahiko Yamamoto; Naoki Hattori; Fumiaki Tanaka; Masaaki Hirayama; Yukio Ando; Shu-ichi Ikeda; Gen Sobue
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 4.  Amyloid neuropathies.

Authors:  Susan C Shin; Jessica Robinson-Papp
Journal:  Mt Sinai J Med       Date:  2012 Nov-Dec

Review 5.  [Hereditary transthyretin amyloidosis].

Authors:  E Hund
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 6.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

7.  Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.

Authors:  Joseph D Schonhoft; Cecilia Monteiro; Lars Plate; Yvonne S Eisele; John M Kelly; Daniel Boland; Christopher G Parker; Benjamin F Cravatt; Sergio Teruya; Stephen Helmke; Mathew Maurer; John Berk; Yoshiki Sekijima; Marta Novais; Teresa Coelho; Evan T Powers; Jeffery W Kelly
Journal:  Sci Transl Med       Date:  2017-09-13       Impact factor: 17.956

8.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?

Authors:  Adam J Loavenbruck; Wolfgang Singer; Michelle L Mauermann; Paola Sandroni; P James B Dyck; Morie Gertz; Christopher J Klein; Phillip A Low
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

Review 10.  Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.